Article in mSystems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Yujie LiAnhui Province Key Laboratory of Pollution Damage and Biological Control for Huaihe River Basin, School of Biological and Food Engineering, Fuyang Normal University, Fuyang, China.ORCID 0000-0001-9293-6233
Shihui YuanState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Ping YanState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Shupei ZhaiHuaibei Agricultural Products Quality and Safety Testing Center, Huaibei, Anhui, China.
Zhien HeState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID 0000-0003-4679-7839
Huimin SuState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Zhongliang ZhuDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Qingze HeDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Weifeng XuState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Baolin SunState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID 0000-0002-2896-3015
Funding
Fundamental Research Funds for the Central Universities WK9100000080Fuyang City-Fuyang Normal University Joint Project SXHZ202006National Natural Science Foundation of China 32370184Natural Science Foundation of Anhui Province 2408085MC061Natural Science Key Research Project of Anhui Provincial Department of Education 2025AHGXZK30595Research Start-up Funds of Fuyang Normal University 2025KYQD0099USTC Research Funds of the Double First-Class Initiative YD9100002063
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Staphylococcal accessory regulator SarA-mediated modulation of autolysis and surface charge enables · full record | OpenQuestion